BIOMARKER PROFILING CORE

生物标志物分析核心

• 批准号: 7944901
• 负责人: Mark Mariusz Bouzyk
• 金额: $ 15.23万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-07 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944901
• 关键词: Accounting; Amendment; American; Architecture; Arts; Automation; Bioinformatics; Biological; Biological Markers; Biostatistics Core; Body Fluids; Cancer Center Support Grant; Cancer Grant Supplements (P30); Candidate Disease Gene; Categories; Cell Extracts; Clinic; Clinical; Clinical Laboratory Information Systems; Complex; Core Facility; Coupled; Custom; DNA; DNA Sequence; Data; Data Analyses; Development; Diagnostic; Discipline; Disease; Disease susceptibility; Electrophoresis; Environment; Equipment; Experimental Designs; Fees; Floor; Formalin; Foundations; Fractionation; Freezing; Funding; Gene Expression; Generations; Genetic; Genetic Variation; Genome; Genomics; Genotype; Goals; Grant; Health; High Pressure Liquid Chromatography; Human; Human Genetics; Institutes; International; Label; Laboratories; Link; Liquid Chromatography; Malignant Neoplasms; Management Information Systems; Maps; Mass Spectrum Analysis; Medical; Medical center; Methodology; Microarray Analysis; Microsatellite Repeats; Mind; Molecular; Molecular Profiling; Monoclonal Antibody R24; Mus; National Institute of Neurological Disorders and Stroke; Nautilus; Neurosciences; Operative Surgical Procedures; Paraffin Embedding; Pathologist; Patient Care; Peer Review; Pharmacogenetics; Plasma; Post-Translational Protein Processing; Preparation; Procedures; Proteins; Proteome; Proteomics; Published Comment; Quality Control; RNA; Regulation; Research; Research Personnel; Resource Sharing; Robotics; SNP genotyping; Saliva; Sampling; Services; Software Tools; Source; Susceptibility Gene; System; Technology; Time; Tissues; Translational Research; Translations; United States National Institutes of Health; Universities; Validation; Whole Blood; analytical tool; base; college; computer infrastructure; data acquisition; data management; driving force; gel electrophoresis; genetic analysis; genetic association; genetic technology; high standard; instrumentation; meetings; member; nanoscale; novel; programs; protein profiling; rat genome; research study; square foot; stable isotope; success; tandem mass spectrometry; transcriptomics

The goal of the WCI BPC is to provide state-of-the-art analytical technologies to impact cancer biomarker discovery, development, and clinical translation. The BPC technologies are concentrated in three synergistic disciplines: (1) medical genomics¿ operated out of the Center for Medical Genomics (CMG) and directed by Dr. Mark Bouzyk, (2) microarray analysis¿ operated out of the WCI Microarray Core (WCIMC), and directed by Dr. Carlos Moreno, and (3) proteomics and mass spectrometry (PMSC)¿ operated out of the Proteomics and Mass Spectrometry Facility and directed by Dr. Junmin Peng. The CMG provides state-of-the-art service in DNA extraction (sources that range from whole blood and saliva to formalin-fixed paraffin-embedded tissues), genomic sequencing, genotyping, and SNP detection/typing. The CMG utilizes instrumentation and automation from Qiagen, Applied Biosystems and Beckman Coulter, which are supported by Thermofisher Nautilus Laboratory Information System (LIMS) comprehensive data management architecture. The WCIMC provides services and platforms for expression profiling of fresh, frozen, or formalin-fixed paraffin-embedded tissues that includes equipment from Affymetrix, Applied Biosystems, and Illumina platforms. It provides comprehensive services from RNA preparation, quality control analysis, microarray hybridization, TaqMan QPCR validation, and data analysis. Bioinformatics support is provided to users by a team of analysts using a variety of standard and custom software tools. The PMSC provides a range of technologies and mass spectrometry (MS)-based platforms. Hundreds to thousands of proteins can be identified by orthogonal methodologies including electrophoresis, multiple types of liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Large-scale protein profiling is achieved by label-free direct quantification (DQUAN) or stable isotope dilution MS (e.g. iTRAQ and SILAC) to determine differential expression in normal versus diseased states. PMSC actively pursues new developments in extensive fractionation technologies of tissue or biofluid samples, such as human plasma and CSF, and continuously upgrades its analytical MS capabilities to form a foundation for protein biomarker discovery. Most activities follow CLIA regulations, thereby allowing the facility to generate molecular data that can directly impact patient care. BPC operation under CLIA standards of high-throughput instrumentation for gene expression and genotype determination will meet increasing demands for generation of clinically useable molecular data in the context of NIH-supported translational research. During CY2007, BPC supported peer-reviewed studies from over 40 WCI members from all four programs. Over the last ten years, the core has been funded four times by NIHNCRR (total >$1.1 million; success rate of 80%) with wide PI participation (ranging between 21 and 49 Emory investigators per application) and receiving laudatory comments from the Study Panels.

WCI BPC的目标是提供最先进的分析技术来影响癌症生物标志物 发现，开发和临床翻译。 BPC技术集中在三个协同作用中 学科：（1）医学基因组学在医学基因组中心（CMG）运作，并由 马克·布齐克（Mark Bouzyk）博士，（2）微阵列分析�从WCI微阵列核心（WCIMC）进行操作，并导演 由Carlos Moreno博士和（3）蛋白质组学和质谱法（PMSC）»蛋白质组学操作 和质谱设施，由Junmin Peng博士执导。 CMG提供最先进的服务 在DNA提取中（从全血和唾液到福尔马林固定石蜡的来源 组织），基因组测序，基因分型和SNP检测/打字。 CMG利用仪器和 来自Qiagen，Applied Biosystems和Beckman Coulter的自动化，由Thermofisher支持 Nautilus实验室信息系统（LIMS）综合数据管理体系结构。 WCIMC 提供服务和平台，以表达新鲜，冷冻或福尔马林固定石蜡的表达分析 包括来自Affymetrix的设备，应用生物系统和Illumina平台的组织。它提供 RNA准备，质量控制分析，微阵列杂交，塔克曼的全面服务 QPCR验证和数据分析。一组分析师使用的生物信息学支持使用 各种标准和自定义软件工具。 PMSC提供了一系列技术和质量 基于光谱的平台。可以通过正交识别数百至数千种蛋白质 包括电泳，多种类型的液相色谱法与串联质量的方法 光谱法（LC-MS/MS）。大规模蛋白质分析是通过无标签的直接定量来实现的 （DQUAN）或稳定的同位素稀释MS（例如ITRAQ和SILAC），以确定在 正常状态与否认状态。 PMSC积极追求广泛分数的新发展 组织或生物流体样品（例如人血浆和CSF）的技术，并不断升级其 分析MS能力构成蛋白质生物标志物发现的基础。大多数活动跟随克里亚 法规，从而允许该设施生成可以直接影响患者护理的分子数据。 BPC在高通量仪器的CLIA标准下运行基因表达和基因型 确定将满足不断增长的对临床上可用分子数据的需求 NIH支持的翻译研究。在CY2007期间，BPC支持了40多个的同行评审研究 来自所有四个程序的WCI成员。在过去的十年中，核心已由Nihncrr资助了四次 （总计> 110万美元；成功率为80％），PI参与广泛（范围为21至49 Emory的调查人员每个应用程序）并收到研究小组的赞誉评论。